193 related articles for article (PubMed ID: 33130754)
1. [A Case of Neoadjuvant Chemotherapy with Modified FOLFOXIRI plus Bevacizumab for Transverse Colon Cancer with Invasion of the Gastric Antrum].
Kanto S; Takeji S; Okamura M; Sakikubo M; Tatsumi K; Yasuda S; Kawabe A
Gan To Kagaku Ryoho; 2020 Oct; 47(10):1517-1520. PubMed ID: 33130754
[TBL] [Abstract][Full Text] [Related]
2. [A Case of Complete Pathological Response in a Patient with Advanced Ascending Colon Cancer That Invaded the Liver and Duodenum after FOLFOXIRI plus Bevacizumab Chemotherapy].
Naito A; Kagawa Y; Kawai K; Takeno A; Takeda Y; Ohtsuka M; Suzuki Y; Imasato M; Fujie Y; Nakaba H; Akamatsu H; Murata K
Gan To Kagaku Ryoho; 2020 Feb; 47(2):298-300. PubMed ID: 32381968
[TBL] [Abstract][Full Text] [Related]
3. [A Case of Effective Neoadjuvant Chemotherapy for Transverse Colon Cancer with Extensive Abdominal Wall Invasion].
Kato M; Murata A; Nishikawa S; Tsutsumi S; Yokoyama H; Takahashi K; Morita T
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1692-1694. PubMed ID: 29394745
[TBL] [Abstract][Full Text] [Related]
4. [Transverse Colon Cancer with Peritoneal Metastasis Successfully Treated with mFOLFOX6 plus Bevacizumab-A Case Report].
Takahashi S; Hanaka J; Takahashi M; Goya T
Gan To Kagaku Ryoho; 2020 Jul; 47(7):1125-1127. PubMed ID: 32668867
[TBL] [Abstract][Full Text] [Related]
5. [Two Cases of Advanced Colorectal Cancer Achieving Complete Response by FOLFOXIRI plus Bevacizumab-A Case Report].
Nemoto T; Endo S; Isohata N; Takayanagi D; Nemoto D; Aizawa M; Utano K; Togashi K; Oshibe I; Soeta N; Saito T
Gan To Kagaku Ryoho; 2019 Dec; 46(13):2410-2412. PubMed ID: 32156948
[TBL] [Abstract][Full Text] [Related]
6. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A;
Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906
[TBL] [Abstract][Full Text] [Related]
7. [Locally Advanced Rectal Cancer Curatively Resected after Modified FOLFOXIRI plus Bevacizumab Chemotherapy-A Case Report].
Yamaguchi S; Kobayashi K; Inoue Y; Torashima Y; Ito S; Kanetaka K; Takatsuki M; Eguchi S
Gan To Kagaku Ryoho; 2020 Mar; 47(3):453-455. PubMed ID: 32381914
[TBL] [Abstract][Full Text] [Related]
8. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
[TBL] [Abstract][Full Text] [Related]
9. Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial.
Masi G; Vivaldi C; Fornaro L; Lonardi S; Buccianti P; Sainato A; Marcucci L; Martignetti A; Luca Urso ED; Castagna M; Fontanini G; Bergamo F; Musettini G; Urbani L; Sensi E; Balestri R; Montrone S; Pasqualetti F; Cremolini C; Di Paolo A; Zagonel V; Falcone A
Eur J Cancer; 2019 Mar; 110():32-41. PubMed ID: 30739838
[TBL] [Abstract][Full Text] [Related]
10. [A Case of a Patient with Locally Recurrent Rectal Cancer Who Underwent Surgical Resection after Chemotherapy with FOLFOXIRI plus Bevacizumab].
Shigoka M; Enomoto M; Wada T; Mazaki J; Kuwabara H; Ishizaki T; Ishibashi Y; Nagakawa Y; Katsumata K; Tsuchida A
Gan To Kagaku Ryoho; 2019 Apr; 46(4):796-798. PubMed ID: 31164539
[TBL] [Abstract][Full Text] [Related]
11. Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis.
Shui L; Wu YS; Lin H; Shui P; Sun Q; Chen X
Cell Physiol Biochem; 2018; 48(5):1870-1881. PubMed ID: 30092572
[TBL] [Abstract][Full Text] [Related]
12. [Extended lymphadenectomy for gastric regional lymph node metastasis from transverse colon cancer--a case report].
Nakatsu H; Hazama S; Tomochika S; Sakamoto K; Yoshino S; Oka M
Gan To Kagaku Ryoho; 2009 Nov; 36(12):2217-9. PubMed ID: 20037375
[TBL] [Abstract][Full Text] [Related]
13. [A case of curatively resected sigmoid colon cancer after mFOLFOX6 plus panitumumab neoadjuvant chemotherapy].
Yoshikawa K; Kuwata H; Nakahata Y
Gan To Kagaku Ryoho; 2014 Mar; 41(3):399-401. PubMed ID: 24743293
[TBL] [Abstract][Full Text] [Related]
14. [Analysis on safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (FOLFOXIRI) in advanced colorectal cancer].
Cai Y; Deng R; Hu H; Zhang J; Ling J; Wu Z; Yang L; Li J; Deng Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1045-1050. PubMed ID: 30269326
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
Masi G; Loupakis F; Salvatore L; Fornaro L; Cremolini C; Cupini S; Ciarlo A; Del Monte F; Cortesi E; Amoroso D; Granetto C; Fontanini G; Sensi E; Lupi C; Andreuccetti M; Falcone A
Lancet Oncol; 2010 Sep; 11(9):845-52. PubMed ID: 20702138
[TBL] [Abstract][Full Text] [Related]
16. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Loupakis F; Cremolini C; Masi G; Lonardi S; Zagonel V; Salvatore L; Cortesi E; Tomasello G; Ronzoni M; Spadi R; Zaniboni A; Tonini G; Buonadonna A; Amoroso D; Chiara S; Carlomagno C; Boni C; Allegrini G; Boni L; Falcone A
N Engl J Med; 2014 Oct; 371(17):1609-18. PubMed ID: 25337750
[TBL] [Abstract][Full Text] [Related]
17. Pathologic Complete Response in Patient With ATM Mutation After Neoadjuvant FOLFOXIRI Plus Panitumumab Therapy for Locally Advanced Colon Cancer: A Case Report.
McGillivray E; Farma J; Savage M; Hall MJ; Luo B; Jain R
Clin Colorectal Cancer; 2021 Jun; 20(2):e96-e99. PubMed ID: 33121919
[No Abstract] [Full Text] [Related]
18. [Two Cases of Metastatic Rectal Cancer Patients Who Received Chemotherapy with FOLFOXIRI plus Bevacizumab].
Nishii T; Uchima Y; Yamakoshi Y; Wang E; Nagashima D; Hirakawa T; Aomatsu N; Iwauchi T; Morimoto J; Nakazawa K; Tei S; Takeuchi K
Gan To Kagaku Ryoho; 2016 Nov; 43(12):1705-1707. PubMed ID: 28133105
[TBL] [Abstract][Full Text] [Related]
19. Clinical and radiological response with FOLFOXIRI and bevacizumab as third-line therapy after mFOLFOX6 and FOLFIRI failure.
de Melo JV; Vieira de Melo MS; Abad MH
Anticancer Drugs; 2011 Jun; 22 Suppl 2():S19-20. PubMed ID: 21768793
[TBL] [Abstract][Full Text] [Related]
20. [A case of ascending colon cancer with unresectable distant metastases treated by systemic chemotherapy].
Sugimoto K; Tashiro Y; Nagayasu K; Niwa K; Ono S; Ishiyama S; Hata M; Komiyama H; Takahashi M; Yaginuma Y; Kojima Y; Goto M; Tanaka M; Sengoku H; Okuzawa A; Tomiki Y; Sakamoto K
Gan To Kagaku Ryoho; 2010 Jun; 37(6):1167-70. PubMed ID: 20567130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
